On May 4, 2023, Fortune Well featured insights from AFAR Senior Scientific Director Steven Austad, PhD, and Scientific Director Nir Barzilai, MD, in an article on metformin’s potential to target the biology of aging and extend healthspan.
Dr. Barzilai explains the need for the Targeting Aging with Metformin (TAME) Trial to provide proof of concept that a gerotherapeutic like metformin can delay the onset or progression of age-related chronic diseases.
Dr. Austad emphasizes the safety profile of metformin and its relatively low side effects.
Learn more about the TAME trial here.
Read the article, "One of the cheapest diabetes drugs on the market can also slow aging and extend your life span. Here’s how,“ here.
Explore the top breakthroughs changing aging, driven by AFAR experts, here.
